Anti-Diabetes Drugs - Saudi Arabia

The Anti-Diabetes Drugs market in Saudi Arabia is expected to witness a significant growth in revenue, projected to reach US$413.60m by 2024.
This growth is anticipated to continue with an annual growth rate of 6.83% from 2024 to 2029, resulting in a market volume of US$575.60m by 2029.
In comparison to other countries, United States is expected to generate the highest revenue in the Anti-Diabetes Drugs market, with an estimated revenue of US$37.84bn in 2024.
Saudi Arabia is experiencing a surge in the demand for anti-diabetes drugs due to the high prevalence of diabetes in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The demand for Anti-Diabetes Drugs in Saudi Arabia has been on the rise over the past few years.

Customer preferences: The increasing prevalence of diabetes in Saudi Arabia has led to a surge in demand for Anti-Diabetes Drugs. Patients are looking for effective and affordable medications to manage their condition. Additionally, there is a growing preference for oral medications over insulin injections due to convenience and ease of use.

Trends in the market: One of the key trends in the Anti-Diabetes Drugs market in Saudi Arabia is the increasing use of generic drugs. This is driven by the government's efforts to reduce healthcare costs and improve access to affordable medications. As a result, several local and international pharmaceutical companies are focusing on the production of generic versions of popular Anti-Diabetes Drugs.Another trend is the growing popularity of combination therapies. Patients are increasingly using multiple medications to manage their diabetes and associated conditions such as hypertension and high cholesterol. This has led to the development of several combination drugs that offer improved efficacy and convenience.

Local special circumstances: Saudi Arabia has one of the highest rates of diabetes in the world, with an estimated 20% of the population affected by the condition. This has put a significant burden on the healthcare system and has led to increased government spending on diabetes management and prevention programs. Additionally, the country has a large expat population, many of whom come from countries with high rates of diabetes.

Underlying macroeconomic factors: The Anti-Diabetes Drugs market in Saudi Arabia is influenced by several macroeconomic factors such as government policies, healthcare infrastructure, and socio-economic conditions. The government's efforts to reduce healthcare costs and improve access to affordable medications are driving the growth of the generic drugs market. Additionally, the country's growing population and changing lifestyle habits are contributing to the increasing prevalence of diabetes. The healthcare infrastructure in Saudi Arabia is also improving, with several new hospitals and clinics being built across the country. Finally, the country's strong economy and high per capita income are enabling more patients to afford Anti-Diabetes Drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.